EXECUTIVE ENGAGEMENTS
POOL
3341
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
601
Interactions with Platform & by Email
PARTICIPANTS
102
Unique # Participated
VALIDATIONS
29
Responses Validated*
COMPANIES
27
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
122
PAGES
186
EDITION
16
PRICE
USD 5600
CODE
MCP-6195
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics estimated at US$16.9 Billion in the year 2020, is projected to reach a revised size of US$23.8 Billion by 2027, growing at aCAGR of 5% over the period 2020-2027. Stimulant, one of the segments analyzed in the report, is projected to record 4.7% CAGR and reach US$19.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Stimulant segment is readjusted to a revised 6.6% CAGR for the next 7-year period.
The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market in the U.S. is estimated at US$5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2027 trailing a CAGR of 4.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 3.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.
SELECT PLAYERS
Alcobra Ltd.; Amarantus Bioscience Holdings, Inc.; Curemark, LLC; Eli Lilly and Company; Intellipharmaceutics International, Inc.; Janssen Global Services, LLC; Mallinckrodt PLC; Mylan NV; Neos Therapeutics, Inc.; Neurovance, Inc.; Noven Pharmaceuticals, Inc.; Pfizer Inc.; Shire plc; Supernus Pharmaceuticals, Inc.; Tris Pharma, Inc.
SEGMENTS
» Drug Type (Stimulant, Non-Stimulant) » Demography (Adult, Children) » Distribution Channel (Retail Pharmacy, Hospital Pharmacy)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| ADHD Therapeutics: A Primer |
| Recent Market Activity |
| ADHD Therapeutics Market Outlook |
| Factors Driving ADHD Therapeutics Market |
| Changes in Insurance Coverage |
| Addition of Formal Guidelines |
| Low Diagnosis Threshold |
| Advancements in Field of Medicine |
| Unmet Needs |
| Launch of Pipeline Drugs |
| Factors Inhibiting ADHD Therapeutics Market |
| Side Effects Related to Use of Stimulants to Treat ADHD |
| Under-diagnosis of ADHD Condition |
| Reduced Availability of Non-Stimulants in Certain Geographies |
| Competitive Landscape |
| Major ADHD Medications Available in the Market |
| ADHD Medications Approved by FDA |
| Patent Validity for Major ADHD Drugs |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| Alcobra Ltd. (Israel) |
| Amarantus Bioscience Holdings, Inc. (US) |
| Amedra Pharmaceuticals LLC (US) |
| Curemark, LLC. (US) |
| Eli Lilly and Company (US) |
| Intellipharmaceutics International, Inc. (US) |
| Janssen Global Services, LLC (US) |
| Mallinckrodt PLC (Ireland) |
| Mylan N.V. (The Netherlands) |
| Neos Therapeutics, Inc. (US) |
| Neurovance, Inc. (US) |
| Noven Pharmaceuticals, Inc. (US) |
| Pfizer Inc. (US) |
| Shire plc (Ireland) |
| Supernus Pharmaceuticals, Inc. (US) |
| Tris Pharma, Inc. (US) |
| 3. MARKET TRENDS & DRIVERS |
| Biological Psychiatry Gaining Ground |
| Social Media Drives Heightened Awareness |
| Stimulants Dominate the Market but Non-Stimulants Inching Their Way to Popularity |
| Robust Growth in Pediatric ADHD Therapeutic Market to Propel Overall Market |
| Strategic Alliances |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Stimulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Non-Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Non-Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Non-Stimulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Children by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 27 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com